- The FDA has approved the use of Vertex Pharmaceuticals' (NASDAQ:VRTX) Kalydeco (ivacaftor) for the treatment of cystic fibrosis patients with 33 genetic mutations, up from 10 mutations.
- The agency based its approval, in part, on laboratory test results. It used these data with results from earlier clinical trials as the basis for its decision, providing a pathway for adding additional CF-related mutations.
- Shares are up 1% after hours on increased volume.
FDA OKs expanded use of Vertex's CF med Kalydeco; shares ahead 1% after hours
Recommended For You
More Trending News
About VRTX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
VRTX | - | - |
Vertex Pharmaceuticals Incorporated |